Bioasis Technologies Inc. (BIOAF)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Bioasis Technologies Inc. (BIOAF) with AI Score 47/100 (Weak). Bioasis Technologies Inc. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 16, 2026Bioasis Technologies Inc. (BIOAF) Healthcare & Pipeline Overview
Bioasis Technologies Inc. is a development-stage biopharmaceutical company specializing in neurological disease treatments. Its xB3 platform facilitates drug delivery across the blood-brain barrier, targeting conditions like brain metastases and glioblastoma. With strategic research collaborations, Bioasis aims to advance novel therapies for central nervous system disorders, positioning itself within the competitive biotechnology landscape.
Investment Thesis
Bioasis Technologies Inc. presents a high-risk, high-reward investment opportunity centered on its xB3 platform technology for delivering therapeutics across the blood-brain barrier. The company's value is primarily driven by the potential success of its pipeline programs targeting brain metastases (xB3-001), glioblastoma (xB3-002), and neurodegenerative diseases (xB3-007). Strategic collaborations with companies like Janssen Biotech and Neuramedy Co Ltd. provide validation of the xB3 platform and potential revenue streams through licensing and commercialization agreements. However, the company's negative profit margin of -7846.5% and gross margin of -45.6% highlight its reliance on future clinical and commercial success. Key catalysts include advancement of clinical trials and expansion of partnerships, while risks involve clinical trial failures, regulatory hurdles, and funding constraints.
Based on FMP financials and quantitative analysis
Key Highlights
- Bioasis Technologies Inc. is a development stage biopharmaceutical company focused on neurological diseases.
- The company's xB3 platform technology facilitates drug delivery across the blood-brain barrier.
- The company has a negative profit margin of -7846.5% reflecting its development stage.
- Gross margin is -45.6%, indicating that the company's cost of revenue exceeds its revenue.
- The company has a beta of 1.74, suggesting higher volatility compared to the market.
Competitors & Peers
Strengths
- Proprietary xB3 platform technology.
- Research collaborations with established pharmaceutical companies.
- Pipeline of drug candidates targeting unmet medical needs.
- Experienced management team with expertise in drug development.
Weaknesses
- Development stage company with no approved products.
- High reliance on research and development funding.
- Negative profit margin and gross margin.
- Limited financial resources compared to larger pharmaceutical companies.
Catalysts
- Upcoming: Announcement of results from preclinical studies of xB3-001 for brain metastases.
- Upcoming: Initiation of clinical trials for xB3-002 in glioblastoma patients.
- Ongoing: Continued progress in research collaborations with Janssen Biotech and Neuramedy Co Ltd.
- Ongoing: Expansion of the xB3 platform to new therapeutic areas.
- Ongoing: Potential for new licensing agreements with pharmaceutical companies.
Risks
- Potential: Clinical trial failures and regulatory approval delays.
- Potential: Competition from other pharmaceutical companies developing treatments for neurological diseases.
- Potential: Patent expiration and intellectual property challenges.
- Ongoing: Reliance on research and development funding.
- Ongoing: Negative profit margin and gross margin.
Growth Opportunities
- Advancement of xB3-001 for Brain Metastases: Bioasis has the opportunity to advance xB3-001 through clinical trials, targeting brain metastases, a condition with limited treatment options. The market for brain metastases treatment is projected to grow as the incidence of cancer increases. Successful clinical trials and regulatory approval could lead to significant revenue generation. The timeline for this growth opportunity depends on the progress of clinical trials, with potential for initial results within the next 2-3 years.
- Development of xB3-002 for Glioblastoma: Glioblastoma, an aggressive brain cancer, represents a significant unmet medical need. Bioasis's xB3-002 aims to address this need by delivering therapeutic agents across the blood-brain barrier. The glioblastoma treatment market is substantial, offering a significant revenue opportunity if xB3-002 proves effective. Clinical trials are essential for advancing this program, with potential for initial data within the next 3-4 years.
- Expansion of xB3-007 for Neurodegenerative Diseases: Bioasis is developing xB3-007 for neurodegenerative diseases, including Alzheimer's and Parkinson's. These diseases affect millions worldwide, creating a large market for effective treatments. The company can expand its focus on specific neurodegenerative diseases and partner with other companies to accelerate development. The timeline for this growth opportunity depends on preclinical and clinical studies, with potential for initial results within the next 4-5 years.
- Strategic Collaborations and Licensing Agreements: Bioasis can leverage its xB3 platform by forming strategic collaborations and licensing agreements with other pharmaceutical companies. These partnerships can provide funding for research and development, as well as access to new markets. The collaboration with Janssen Biotech, Inc. demonstrates the potential for such partnerships. Expanding these collaborations can accelerate the development and commercialization of xB3-based therapies. This growth opportunity is ongoing, with potential for new partnerships in the near future.
- Application of xB3 Platform to New Therapeutic Areas: Bioasis can explore the application of its xB3 platform to new therapeutic areas beyond brain cancers and neurodegenerative diseases. The platform's ability to cross the blood-brain barrier makes it potentially valuable for treating a wide range of CNS disorders. Expanding the platform's applications can create new revenue streams and diversify the company's pipeline. This growth opportunity is long-term, with potential for new applications to emerge over the next 5-7 years.
Opportunities
- Expansion of xB3 platform to new therapeutic areas.
- Strategic collaborations and licensing agreements.
- Advancement of drug candidates through clinical trials.
- Potential for breakthrough therapies for neurological diseases.
Threats
- Clinical trial failures.
- Regulatory hurdles and approval delays.
- Competition from other pharmaceutical companies.
- Patent expiration and intellectual property challenges.
Competitive Advantages
- Proprietary xB3 platform technology for crossing the blood-brain barrier.
- Established research collaborations with pharmaceutical companies.
- Pipeline of drug candidates targeting specific neurological diseases.
- Intellectual property protection for xB3 technology and related applications.
About BIOAF
Bioasis Technologies Inc., founded in 2006 and headquartered in New Haven, Connecticut, is a development stage biopharmaceutical company focused on creating innovative treatments for neurological diseases and disorders. The company's core technology is the xB3 platform, designed to transport therapeutic agents across the blood-brain barrier (BBB), a significant challenge in treating central nervous system (CNS) disorders. Bioasis is developing treatments for brain cancers, metabolic diseases, and neurodegenerative diseases. Its in-house development programs include xB3-001 for brain metastases, xB3-002 for glioblastoma, and xB3-007 for neurodegenerative diseases. Bioasis has established research collaborations to expand the application of its xB3 platform. These collaborations include partnerships with Aposense Limited for siRNA therapeutics delivery to treat CNS disorders, Oxyrane UK Ltd. to combine xB3 technology with Oxyrane's OxyCAT platform for enhanced enzyme replacement therapy delivery into the brain, and Janssen Biotech, Inc. to research, develop, and commercialize novel products based on the xB3 platform. Additionally, Bioasis has a research collaboration and license agreement with Neuramedy Co Ltd. to develop and commercialize an xB3TM version of its antibody, Tomaralimab. As a development stage company, Bioasis is focused on advancing its pipeline through preclinical and clinical development, aiming to address unmet medical needs in the treatment of neurological disorders.
What They Do
- Develop xB3 platform technology for drug delivery across the blood-brain barrier.
- Research and develop treatments for neurological diseases and disorders.
- Focus on therapies for brain metastases, glioblastoma, and neurodegenerative diseases.
- Collaborate with other companies to expand the application of xB3 technology.
- Develop symptomatic and disease-modifying treatments for CNS disorders.
- Seek to commercialize novel products based on the xB3 platform.
Business Model
- Develop and out-license xB3 platform technology to other pharmaceutical companies.
- Generate revenue through research collaborations and licensing agreements.
- Advance internal drug development programs through preclinical and clinical trials.
- Potentially generate revenue through the sale of approved therapies.
Industry Context
Bioasis Technologies Inc. operates within the biotechnology industry, which is characterized by high research and development costs, lengthy regulatory approval processes, and significant competition. The company focuses on developing treatments for neurological diseases, a market with substantial unmet needs and growth potential. The blood-brain barrier (BBB) presents a significant challenge in treating CNS disorders, making Bioasis's xB3 platform a potentially valuable asset. The biotechnology industry is driven by innovation, with companies constantly seeking to develop novel therapies and improve existing treatments. Competition includes companies such as BLFE, BNYN, EMYSF, GBLX, and GSTC, which are developing treatments for neurological disorders.
Key Customers
- Pharmaceutical companies seeking drug delivery solutions for CNS disorders.
- Patients suffering from brain metastases, glioblastoma, and neurodegenerative diseases.
- Research institutions interested in collaborating on drug development.
- Strategic partners seeking to develop and commercialize xB3-based therapies.
Financials
Chart & Info
Bioasis Technologies Inc. (BIOAF) stock price: Price data unavailable
Latest News
-
Stocks That Hit 52-Week Lows On Monday
· Oct 21, 2019
-
Stocks That Fell Through 52-Week Lows Wednesday
· Aug 7, 2019
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for BIOAF.
Price Targets
Wall Street price target analysis for BIOAF.
MoonshotScore
What does this score mean?
The MoonshotScore rates BIOAF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Deborah Ann Rathjen
CEO
Deborah Ann Rathjen serves as the CEO of Bioasis Technologies Inc. Her background includes extensive experience in the biotechnology and pharmaceutical industries. She has held leadership positions in various companies, focusing on drug development and commercialization. Her expertise spans strategic planning, business development, and clinical operations. Rathjen's experience includes roles in both large pharmaceutical companies and smaller biotechnology firms, providing her with a broad understanding of the industry landscape. She has a strong track record of driving innovation and growth in the healthcare sector.
Track Record: Under Deborah Ann Rathjen's leadership, Bioasis Technologies Inc. has focused on advancing its xB3 platform and pipeline of drug candidates. She has overseen the establishment of strategic collaborations with companies like Janssen Biotech and Neuramedy Co Ltd., which have validated the potential of the xB3 technology. Her tenure has been marked by efforts to secure funding for research and development and to navigate the regulatory landscape. She has focused on building a strong team and fostering a culture of innovation within the company.
BIOAF OTC Market Information
Bioasis Technologies Inc. trades on the OTC Other tier, which represents the lowest tier of the OTC market. Unlike stocks listed on major exchanges like the NYSE or NASDAQ, OTC Other stocks often have limited regulatory oversight and reporting requirements. Companies on this tier may not meet minimum financial standards or listing requirements of major exchanges. This can result in less transparency and increased risk for investors. OTC Other stocks typically have lower trading volumes and wider bid-ask spreads compared to exchange-listed stocks.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited regulatory oversight and reporting requirements.
- Lower trading volume and wider bid-ask spreads.
- Increased price volatility.
- Potential for limited financial information.
- Higher risk of fraud or manipulation.
- Verify the company's financial statements and SEC filings, if available.
- Research the company's management team and their track record.
- Assess the company's business model and competitive landscape.
- Evaluate the company's intellectual property and patent protection.
- Understand the company's capital structure and funding sources.
- Monitor news and press releases for updates on the company's progress.
- Consult with a financial advisor before investing.
- Research collaborations with established pharmaceutical companies.
- Development of proprietary xB3 platform technology.
- Pipeline of drug candidates targeting specific neurological diseases.
- Experienced management team with expertise in drug development.
Bioasis Technologies Inc. Stock: Key Questions Answered
What does Bioasis Technologies Inc. do?
Bioasis Technologies Inc. is a development-stage biopharmaceutical company focused on creating treatments for neurological diseases and disorders. The company's core technology is the xB3 platform, which facilitates the transport of therapeutic agents across the blood-brain barrier (BBB). Bioasis is developing treatments for brain metastases, glioblastoma, and neurodegenerative diseases. The company collaborates with other pharmaceutical companies to expand the application of its xB3 technology and advance its pipeline of drug candidates. Bioasis aims to address unmet medical needs in the treatment of neurological disorders through its innovative platform and strategic partnerships.
What do analysts say about BIOAF stock?
As of 2026-03-16, there is no readily available analyst consensus on BIOAF stock due to its OTC listing and development stage. Key valuation metrics such as price-to-earnings ratio (-0.12) and profit margin (-7846.5%) reflect the company's current lack of profitability. Growth considerations center on the successful development and commercialization of its xB3 platform and pipeline programs. Investors should conduct thorough due diligence and consider the inherent risks associated with investing in development-stage biotechnology companies. The company's potential lies in its innovative technology and strategic collaborations, but its financial performance is highly dependent on future clinical and regulatory success.
What are the main risks for BIOAF?
The main risks for Bioasis Technologies Inc. include clinical trial failures, regulatory hurdles, and competition from other pharmaceutical companies. The company's xB3 platform and drug candidates may not prove effective or safe in clinical trials, leading to delays or termination of development programs. Regulatory approval processes can be lengthy and uncertain, potentially delaying or preventing the commercialization of new therapies. Bioasis faces competition from larger pharmaceutical companies with greater resources and established market positions. The company's reliance on research and development funding also poses a risk, as funding may not be available on favorable terms or at all. Additionally, patent expiration and intellectual property challenges could impact the company's competitive advantage.
What are the key factors to evaluate for BIOAF?
Bioasis Technologies Inc. (BIOAF) currently holds an AI score of 47/100, indicating low score. Key strength: Proprietary xB3 platform technology.. Primary risk to monitor: Potential: Clinical trial failures and regulatory approval delays.. This is not financial advice.
How frequently does BIOAF data refresh on this page?
BIOAF prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven BIOAF's recent stock price performance?
Recent price movement in Bioasis Technologies Inc. (BIOAF) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Proprietary xB3 platform technology.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider BIOAF overvalued or undervalued right now?
Determining whether Bioasis Technologies Inc. (BIOAF) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying BIOAF?
Before investing in Bioasis Technologies Inc. (BIOAF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available company data and may be subject to change.
- OTC market data may be less reliable than exchange-listed data.